We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
-1.98%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$868M
AUM Growth
+$59.7M
Cap. Flow
+$69.5M
Cap. Flow %
8.01%
Top 10 Hldgs %
48.78%
Holding
127
New
31
Increased
30
Reduced
21
Closed
29

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$14.1M
2
APGE icon
Apogee Therapeutics
APGE
+$11.9M
3
CLYM
Climb Bio
CLYM
+$11.1M
4
ACLX
Arcellx
ACLX
+$8.7M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$8.33M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$9.7M
2
ABSI icon
Absci
ABSI
+$5.82M
3
CYTK icon
Cytokinetics
CYTK
+$5.61M
4
KRYS icon
Krystal Biotech
KRYS
+$4.76M
5
AXSM icon
Axsome Therapeutics
AXSM
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 65.41%
2 Financials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
101
CALL
CRISPR Therapeutics
CRSP
$4.68B
– –
-65,000
Closed -$4.43M
CYTK icon
102
Cytokinetics
CYTK
$11.1B
– –
-80,000
Closed -$5.61M
ESTA icon
103
CALL
Establishment Labs
ESTA
$2.68B
– –
-50,000
Closed -$2.54M
FULC icon
104
Fulcrum Therapeutics
FULC
$251M
– –
-550,339
Closed -$4.17M
GH icon
105
CALL
Guardant Health
GH
$19.9B
– –
-250,000
Closed -$5.16M
CBIO
106
PUT
Crescent Biopharma
CBIO
$629M
– –
-1,423
Closed -$427K
IBRX icon
107
PUT
ImmunityBio
IBRX
$7.75B
– –
-589,400
Closed -$3.17M
IRWD icon
108
CALL
Ironwood Pharmaceuticals
IRWD
$624M
– –
-1,029,500
Closed -$8.97M
KRYS icon
109
Krystal Biotech
KRYS
$9.65B
– –
-26,746
Closed -$4.76M
MLTX icon
110
MoonLake Immunotherapeutics
MLTX
$1.62B
– –
-75,000
Closed -$3.77M
MRNA icon
111
PUT
Moderna
MRNA
$22.6B
– –
-400,000
Closed -$42.6M
PTGX icon
112
Protagonist Therapeutics
PTGX
$8.71B
– –
-100,000
Closed -$2.89M
RAPT
113
CALL
DELISTED
RAPT Therapeutics
RAPT
– –
-7,500
Closed -$539K
RGNX icon
114
Regenxbio
RGNX
$656M
– –
-110,000
Closed -$2.32M
TERN
115
DELISTED
Terns Pharmaceuticals
TERN
– –
-450,000
Closed -$2.95M
TRML
116
DELISTED
Tourmaline Bio
TRML
– –
-50,000
Closed -$1.15M
TVTX icon
117
Travere Therapeutics
TVTX
$5.27B
– –
-125,000
Closed -$964K
VKTX icon
118
Viking Therapeutics
VKTX
$4.11B
– –
-50,000
Closed -$4.1M
XBI icon
119
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
– –
-700,000
Closed -$66.4M
ITCI
120
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-50,000
Closed -$3.46M
GRTS
121
PUT
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
– –
-2,390,600
Closed -$6.14M
SAVAW
122
DELISTED
Cassava Sciences, Inc. Warrant
SAVAW
– –
-24,200
Closed -$97.5K
1 2 3 4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return

Affinity Asset Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Affinity Asset Advisors held 127 positions worth $868M, up 7.4% from $808M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Affinity Asset Advisors deployed $69.5M of net new capital in Q2 2024, opening 31 new positions and adding to 30 existing holdings. Its largest new stake was Climb Bio: 1,670,661 shares worth $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 71% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $4.42M trimmed.

  • Affinity Asset Advisors's largest Q2 2024 buy was Climb Bio: 1,670,661 shares worth $11.9M.
  • Affinity Asset Advisors added most to Alkermes in Q2 2024, an estimated $14.1M increase.
  • Affinity Asset Advisors's biggest Q2 2024 reduction was Axsome Therapeutics, cutting an estimated $4.42M.
  • Affinity Asset Advisors fully exited Apellis Pharmaceuticals in Q2 2024, selling an estimated $9.7M.
  • Affinity Asset Advisors's ten largest holdings make up 49% of its $868M portfolio in Q2 2024.
  • Affinity Asset Advisors opened 31 new positions and closed 29 in Q2 2024.
  • Affinity Asset Advisors's portfolio value rose 7.4% quarter-over-quarter to $868M.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.